Selinexor, Mezigdomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Relapsing / Ineligible for T-Cell-Redirecting Therapy (TCRT): STOMP Phase 1 Preliminary Results

Blenrep (belantamab mafodotin-blmf) - GSK

Neupogen (filgrastim) - Kyowa Kirin, Amgen

dexamethasone - Generic mfg.

Talvey (talquetamab-tgvs) - J&J

mezigdomide (CC-92480) - BMS

Carvykti (ciltacabtagene autoleucel) - J&J

IGM-2644 - IGM Biosciences

Xpovio (selinexor) - Karyopharm

https://imsannual2026.eventscribe.net/ajaxcalls/PosterInfo.asp?efp=TU1XRFNPTlIyMjY0Nw&PosterID=826571&rnd=0.3477264

Redirecting Therapy (TCRT): STOMP Phase 1 Preliminary Results Clifton Mo1; Cristina Gasparetto2; Cristiana Costa2; Andrew J. Cowan3; Tomer Mark4; Yi Chai4; Trinayan Kashyap4; Jessica Katz5; Michael Amatangelo5; Paul G. Richardson1

Sep 11, 2026